



Agenus to Webcast Annual Meeting of Stockholders

June 8, 2016

LEXINGTON, Mass.--([BUSINESS WIRE](#))--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Tuesday, June 14, 2016. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.

Webcast Information

A live webcast will be accessible from the Company's website at www.agenusbio.com/webcast. The archived replay will be available on the Agenus website for at least 30 days following the meeting.

About Agenus

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, the Company's cancer vaccine program includes three proprietary platforms focused on individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus' broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Contact:

Agenus Inc.
Michelle Linn, 781-674-4541
michelle.linn@agenusbio.com